title: Anthrax toxin-mediated delivery of the Pseudomonas exotoxin A enzymatic domain to the cytosol of tumor cells via cleavable ubiquitin fusions.
abstract: Anthrax toxin proteins from Bacillus anthracis constitute a highly efficient system for delivering cytotoxic enzymes to the cytosol of tumor cells. However, exogenous proteins delivered to the cytosol of cells are subject to ubiquitination on lysines and proteasomal degradation, which limit their potency. We created fusion proteins containing modified ubiquitins with their C-terminal regions fused to the Pseudomonas exotoxin A catalytic domain (PEIII) in order to achieve delivery and release of PEIII to the cytosol. Fusion proteins in which all seven lysines of wild-type ubiquitin were retained while the site cleaved by cytosolic deubiquitinating enzymes (DUBs) was removed were nontoxic, apparently due to rapid ubiquitination and proteasomal degradation. Fusion proteins in which all lysines of wild-type ubiquitin were substituted by arginine had high potency, exceeding that of a simple fusion lacking ubiquitin. This variant was less toxic to nontumor tissues in mice than the fusion protein lacking ubiquitin and was very efficient for tumor treatment in mice. The potency of these proteins was highly dependent on the number of lysines retained in the ubiquitin domain and on retention of the C-terminal ubiquitin sequence cleaved by DUBs. It appears that rapid cytosolic release of a cytotoxic enzyme (e.g., PEIII) that is itself resistant to ubiquitination is an effective strategy for enhancing the potency of tumor-targeting toxins.
  
  
  OBJECTIVE
  Bacterial toxins typically have highly efficient mechanisms for cellular delivery of their enzymatic components. Cytosolic delivery of therapeutic enzymes and drugs is an important topic in molecular medicine. We describe anthrax toxin fusion proteins containing ubiquitin as a cytosolic cleavable linker that improves the delivery of an enzyme to mammalian cells. The ubiquitin linker allowed modulation of potency in cells and in mice. This effective strategy for enhancing the intracellular potency of an enzyme may be useful for the cytosolic delivery and release of internalized drugs.
authors: Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
authors: Christopher
authors: C
authors: Bachran
authors: Thomas
authors: T
authors: Morley
authors: Suzanne
authors: S
authors: Abdelazim
authors: Rasem J
authors: RJ
authors: Fattah
authors: Shihui
authors: S
authors: Liu
authors: Stephen H
authors: SH
authors: Leppla
mesh_terms: D036002:ADP Ribose Transferases / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D000942:Antigens, Bacterial / Q000235:genetics / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001427:Bacterial Toxins / Q000235:genetics / Q000378:metabolism*; D001688:Biological Products / Q000008:administration & dosage; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D003600:Cytosol / Q000378:metabolism*; D004195:Disease Models, Animal; D005098:Exotoxins / Q000235:genetics / Q000378:metabolism*; D005260:Female; D051379:Mice; D008810:Mice, Inbred C57BL; D009369:Neoplasms / Q000188:drug therapy; D059748:Proteolysis; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D016896:Treatment Outcome; D025801:Ubiquitin / Q000235:genetics / Q000378:metabolism*; D037521:Virulence Factors / Q000235:genetics / Q000378:metabolism*; D000097668:Pseudomonas aeruginosa Exotoxin A
chemical_list: D036002:ADP Ribose Transferases; D000942:Antigens, Bacterial; D000970:Antineoplastic Agents; D001427:Bacterial Toxins; D001688:Biological Products; D002352:Carrier Proteins; D005098:Exotoxins; D011993:Recombinant Fusion Proteins; D025801:Ubiquitin; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A; C030325:anthrax toxin
references: Mol Microbiol. 2011 May;80(3):588-95
references: 21443527
references: J Neurosci. 2005 Feb 23;25(8):2002-9
references: 15728840
references: J Biol Chem. 2003 Feb 14;278(7):5227-34
references: 12468536
references: Biochemistry. 1998 Nov 10;37(45):15737-46
references: 9843379
references: Nat Biotechnol. 2005 Jun;23(6):725-30
references: 15895075
references: J Biol Chem. 2008 Jan 4;283(1):529-540
references: 17974567
references: J Biol Chem. 2000 Feb 11;275(6):4363-8
references: 10660606
references: Clin Chem. 2007 Sep;53(9):1676-83
references: 17712004
references: EMBO J. 1998 Jan 15;17(2):615-25
references: 9430652
references: Nat Methods. 2006 Apr;3(4):259-61
references: 16554829
references: J Biol Chem. 1993 Feb 15;268(5):3334-41
references: 8429009
references: Methods Enzymol. 2005;399:777-99
references: 16338395
references: PLoS One. 2008 Sep 03;3(9):e3130
references: 18769623
references: Protein Sci. 2011 Aug;20(8):1298-345
references: 21633985
references: Mol Microbiol. 2011 Sep;81(5):1390-401
references: 21797942
references: Cell Cycle. 2008 Mar 15;7(6):745-9
references: 18245947
references: Mol Microbiol. 2008 Sep;69(5):1221-33
references: 18627462
references: Cell Microbiol. 2007 Apr;9(4):977-87
references: 17381430
references: Dev Genes Evol. 1999 Jan;209(1):63-8
references: 9914420
references: Cancer Res. 2007 Oct 1;67(19):9472-81
references: 17909057
references: Annu Rev Biochem. 2009;78:363-97
references: 19489724
references: Infect Immun. 1994 Nov;62(11):4955-61
references: 7927776
references: J Biol Chem. 2007 Jun 15;282(24):17375-86
references: 17426036
references: ACS Chem Biol. 2010 Aug 20;5(8):747-52
references: 20545362
references: Carcinogenesis. 1994 Dec;15(12):2683-6
references: 8001221
references: Infect Immun. 2009 Oct;77(10):4327-36
references: 19635822
references: Mol Cancer Ther. 2006 Oct;5(10):2556-62
references: 17041100
references: J Mol Biol. 2011 Feb 25;406(3):454-66
references: 21185309
references: Biochem J. 2000 Jan 15;345 Pt 2:247-54
references: 10620501
references: J Biol Chem. 1994 Nov 18;269(46):29039-46
references: 7961869
references: Int J Cancer. 2003 Jan 10;103(2):277-82
references: 12455044
references: Nat Biotechnol. 2000 Dec;18(12):1298-302
references: 11101811
references: Clin Cancer Res. 2010 Apr 15;16(8):2284-94
references: 20371697
references: PLoS One. 2009 Nov 23;4(11):e7946
references: 19956758
references: EMBO J. 2000 Jan 4;19(1):94-102
references: 10619848
references: Curr Pharm Des. 2009;15(23):2700-11
references: 19689340
references: J Biol Chem. 2009 Dec 18;284(51):35485-94
references: 19858201
references: J Immunother. 2009 Sep;32(7):713-25
references: 19561537
references: Int J Immunopharmacol. 1992 Feb;14(2):281-91
references: 1624227
references: Biochem Biophys Res Commun. 1989 Apr 14;160(1):333-9
references: 2496688
references: FEBS J. 2011 Dec;278(23):4683-700
references: 21585657
references: Mol Ther. 2005 Feb;11(2):196-204
references: 15668131
references: Biochem Biophys Res Commun. 1978 Mar 30;81(2):532-8
references: 96821
references: Cancer Res. 2000 Nov 1;60(21):6061-7
references: 11085528
references: J Biol Chem. 2001 Dec 7;276(49):46326-32
references: 11574549